Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

01-04-2015 | Research Article

Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma

Authors: Pallavi Singhal, Anoop Kumar, Soham Bharadwaj, Showket Hussain, Mausumi Bharadwaj

Published in: Tumor Biology | Issue 4/2015

Login to get access

Abstract

Aim

Cervical cancer is the most common gynecological malignancy in the developing countries like India. In addition to human papillomavirus (HPV) infection, host genetic factors play an important role in viral persistence and neoplastic growth. IL-10, a multifunctional cytokine, plays an active role to promote tumor growth in the presence of HPV. The present study aims to find out the impact of IL-10 promoter polymorphisms at -1082A/G (rs1800896), -819C/T (rs1800872), and -592C/A (rs1800871) sites along with IL-10 production and HPV infection in the progression of cervical cancer.

Methods

We have genotyped a total of 506 subjects, 256 cases (208 cervical cancer + 48 precancer), and 250 healthy controls by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method followed by sequencing. IL-10 serum concentration was measured by enzyme-linked immunosorbent assay.

Results

The frequency of IL-10 -592 variant genotype (AA) was found significantly reduced in cases as compare to controls while -1082 variant genotype (GG) was found ~4-fold higher risk of cervical cancer (p = <0.0001, OR = 3.667, 95 % CI = 2.329–5.773). On construction of haplotypes, GTC haplotype was emerged as a major risk haplotype while ACA haplotype was seemed as a marker for precancerous lesions. IL-10 serum concentration was observed higher in HPV-infected precancer and cancer cases. GTC haplotype was found to be coupled with higher serum concentration of IL-10 and HPV infection.

Conclusion

IL-10 polymorphisms play a role in cervical cancer development and that GTC haplotype, which is closely related to its serum concentration, maybe a useful biomarker for HPV-mediated cervical cancer.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11; 2013.
2.
Kohaar I, Hussain S, Thakur N, Tiwari P, Nasare V, Batra S, et al. Association between human leukocyte antigen class II alleles and human papillomavirus-mediated cervical cancer in Indian women. Hum Immunol. 2009;70:222–9.CrossRefPubMed
3.
Zur HH. Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55–78.
4.
Wu TC. Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol. 1994;6:746–54.CrossRefPubMed
5.
Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Natl Cancer Inst. 1997;89:185–7.CrossRefPubMed
6.
Clerici M, Shearer GM, Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst. 1998;90:261–3.CrossRefPubMed
7.
Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics. 1997;46:120–8.CrossRefPubMed
8.
Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. 2003;24:36–43.CrossRefPubMed
9.
Woodworth CD, Lichti U, Simpson S, Evans CH, DiPaolo JA. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res. 1992;52:456–63.PubMed
10.
Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Penalver M, et al. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol. 1997;64:18–25.CrossRefPubMed
11.
Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, et al. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res. 2008;28:309–14.PubMed
12.
Burada F, Dumitrescu T, Nicoli R, Ciurea ME, Rogoveanu I, Ioana M. Cytokine promoter polymorphisms and risk of colorectal cancer. Clin Lab. 2013;59:773–9.CrossRefPubMed
13.
Liu P, Song J, Su H, Li L, Lu N, Yang R, et al. IL-10 gene polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. PLoS One. 2013;8:e69547.CrossRefPubMedPubMedCentral
14.
Tsai CW, Tsai MH, Shih LC, Chang WS, Lin CC, Bau DT. Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. Anticancer Res. 2013;33:3391–6.PubMed
15.
Wu Z, Zheng W, Xu J, Sun F, Chen H, Li P, Chen S, Shen M, Zhang W, You X, Wu Q, Zhang F, Li Y: IL10 polymorphisms associated with Behcet's disease in Chinese Han. Hum Immunol 2013.
16.
Zheng XY, Guan WJ, Mao C, Chen HF, Ding H, Zheng JP, et al. Interleukin-10 promoter 1082/-819/-592 polymorphisms are associated with asthma susceptibility in Asians and atopic asthma: a meta-analysis. Lung. 2014;192:65–73.CrossRefPubMed
17.
Zou L, Wang L, Gong X, Zhao H, Jiang A, Zheng S: The association between three promoter polymorphisms of IL-10 and inflammatory bowel diseases (IBD): A meta-analysis. Autoimmunity 2013.
18.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.CrossRefPubMed
19.
Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349:170–3.CrossRefPubMed
20.
Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239:487–91.CrossRefPubMed
21.
Sambrook Ra: Molecular Cloninig: A laboratory manual.; Cold Spring Harbor Laboratory Press 3, 2001.
22.
Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinski SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells. 1989;7:pp 209–14.
23.
Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002;184:57–63.CrossRefPubMed
24.
Shekari M, Kordi-Tamandani DM, MalekZadeh K, Sobti RC, Karimi S, Suri V. Effect of anti-inflammatory (IL-4, IL-10) cytokine genes in relation to risk of cervical carcinoma. Am J Clin Oncol. 2012;35:514–9.CrossRefPubMed
25.
Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005;15 Suppl 3:282–90.CrossRefPubMed
26.
Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer. 2007;121:2451–7.CrossRefPubMed
27.
Singh H, Jain M, Sachan R, Mittal B. Association of TNFA (-308G > A) and IL-10 (-819C > T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer. 2009;19:1190–4.CrossRefPubMed
28.
Matsumoto K, Oki A, Satoh T, Okada S, Minaguchi T, Onuki M, et al. Interleukin-10–1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 2010;40:1113–6.CrossRefPubMed
29.
Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012;33:1549–56.CrossRefPubMed
30.
Ni J, Ye Y, Teng F, Wu Q. Interleukin 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2013;23:126–33.CrossRefPubMed
31.
Wang Q, Zhang C, Walayat S, Chen HW, Wang Y. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol. 2011;158:330–3.CrossRefPubMed
32.
Chagas BS, Gurgel AP, da Cruz HL, Amaral CM, Cardoso MV, Silva Neto JC, et al. An interleukin-10 gene polymorphism associated with the development of cervical lesions in women infected with Human Papillomavirus and using oral contraceptives. Infect Genet Evol. 2013;19:32–7.CrossRefPubMed
33.
Liu J, Song B, Bai X, Liu W, Li Z, Wang J, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer. 2010;10:456.CrossRefPubMedPubMedCentral
34.
Wei YS, Kuang XH, Zhu YH, Liang WB, Yang ZH, Tai SH, et al. Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens. 2007;70:12–7.CrossRefPubMed
35.
Yao JG, Gao LB, Liu YG, Li J, Pang GF. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta. 2008;388:84–8.CrossRefPubMed
36.
de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, van Oostveen JW, Stukart MJ, van Verheijen RH, et al. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer. 1999;35:490–7.CrossRefPubMed
37.
Giannini SL, Al-Saleh W, Piron H, Jacobs N, Doyen J, Boniver J, et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol. 1998;113:183–9.CrossRefPubMedPubMedCentral
38.
Torres-Poveda K, Burguete-Garcia AI, Cruz M, Martinez-Nava GA, Bahena-Roman M, Ortiz-Flores E, et al. The SNP at -592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development. Infect Agent Cancer. 2012;7:32.CrossRefPubMedPubMedCentral
39.
Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94:792–4.CrossRefPubMed
Metadata
Title
Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma
Authors
Pallavi Singhal
Anoop Kumar
Soham Bharadwaj
Showket Hussain
Mausumi Bharadwaj
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2836-6

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

7SK small nuclear RNA inhibits cancer cell proliferation through apoptosis induction

Research Article

Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China

Research Article

MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met

Research Article

Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer

Research Article

Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast

Research Article

Clinicopathological and cellular signature of PAK1 in human bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits